Related Experiment Video
Updated: Oct 5, 2025
Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
Multisystem Inflammatory Syndrome in Children: Examining Emerging Data and Identifying Key Knowledge Gaps
Laura F Sartori1, Fran Balamuth
1From the Assistant Professor and Associate Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania; and Division of Pediatric Emergency Medicine and Pediatric Sepsis Program, Children's Hospital of Philadelphia, Philadelphia, PA.
Insights
Multisystem inflammatory syndrome in children (MIS-C) is a rare immune response to COVID-19, affecting children and causing organ damage. MIS-C has distinct features from Kawasaki disease, but treatment guidelines are still developing.
Area of Science:
- Pediatric infectious diseases
- Immunology
- Cardiovascular medicine
Background:
- Multisystem inflammatory syndrome in children (MIS-C) is a serious condition following SARS-CoV-2 infection.
- MIS-C can lead to significant organ dysfunction, particularly severe cardiovascular compromise in children.
- Evidence suggests MIS-C differs clinically and in laboratory findings from Kawasaki disease.
Purpose of the Study:
- To delineate the distinct clinical and laboratory features of MIS-C compared to Kawasaki disease.
- To highlight the need for evidence-based treatment strategies and long-term outcome data for MIS-C.
Main Methods:
- Comparative analysis of clinical presentations and laboratory results in children with MIS-C and Kawasaki disease.
- Review of existing literature on MIS-C pathophysiology and clinical manifestations.
Main Results:
- MIS-C typically affects older children than Kawasaki disease.
- MIS-C is associated with more pronounced gastrointestinal and neurological symptoms.
- Laboratory findings in MIS-C often show increased inflammation, lymphopenia, and cardiac injury.
Conclusions:
- MIS-C presents a distinct profile compared to Kawasaki disease, necessitating specific diagnostic and management approaches.
- Further research is crucial to establish best practices for MIS-C treatment and understand its long-term consequences.
Abstract:
Multisystem inflammatory syndrome in children (MIS-C) is a syndrome of abnormal immune response after severe acute respiratory syndrome coronavirus 2 infection that can result in organ dysfunction including severe cardiovascular compromise in children. Increased evidence supports a clinical and laboratory profile in MIS-C distinct from Kawasaki disease, with MIS-C typically occurring in older children and with more prominent gastrointestinal and neurologic symptoms, as well as increased inflammation, lymphopenia, and cardiac injury on laboratory testing. However, high-level evidence regarding best practices for treatment and long-term outcomes in MIS-C is limited.
Related Concept Videos
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism